Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
22 hedge funds and large institutions have $5.61M invested in Statera Biopharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 5 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
161% more capital invested
Capital invested by funds: $2.15M → $5.61M (+$3.46M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 21 → 22 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.62M |
| 2 |
Morgan Stanley
New York
|
+$1.16M |
| 3 |
AIP
ARS Investment Partners
New York
|
+$202K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$197K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.1M |
| 2 |
Renaissance Technologies
New York
|
-$192K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$59K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$52K |
| 5 |
Barclays
London,
United Kingdom
|
-$26K |
STAB Hedge Fund Activity: Q1 2021 in Review
22 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2021, worth a combined $5.61M — up 161% from $2.15M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new STAB positions and 5 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.62M. The largest seller was Armistice Capital, exiting entirely with an estimated $1.1M sold.
- 22 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $5.61M of Statera Biopharma, Inc. Common Stock stock for Q1 2021, up 161% quarter-over-quarter.
- 6 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2021 and 5 closed out, a net change of +1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2021 was Sabby Management, an estimated $2.62M added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q1 2021 was Armistice Capital, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2021.